40,979 Shares in PDS Biotechnology Co. (NASDAQ:PDSB) Bought by Squarepoint Ops LLC

Squarepoint Ops LLC purchased a new position in shares of PDS Biotechnology Co. (NASDAQ:PDSB) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 40,979 shares of the company’s stock, valued at approximately $120,000. Squarepoint Ops LLC owned 0.11% of PDS Biotechnology at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kathleen S. Wright Associates Inc. purchased a new stake in PDS Biotechnology during the 1st quarter worth $28,000. Tempus Wealth Planning LLC purchased a new stake in PDS Biotechnology during the 2nd quarter worth $55,000. Ground Swell Capital LLC purchased a new stake in PDS Biotechnology during the 2nd quarter worth $67,000. Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology during the 2nd quarter worth $146,000. Finally, Blair William & Co. IL grew its holdings in PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after acquiring an additional 81,743 shares in the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Trading Up 3.3 %

NASDAQ PDSB opened at $3.42 on Monday. PDS Biotechnology Co. has a one year low of $2.53 and a one year high of $6.85. The company has a 50-day simple moving average of $3.24 and a 200-day simple moving average of $3.29. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.84 and a current ratio of 3.84. The firm has a market capitalization of $125.44 million, a PE ratio of -2.51 and a beta of 1.90.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the business earned ($0.37) earnings per share. On average, equities analysts forecast that PDS Biotechnology Co. will post -1.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PDSB. HC Wainwright reissued a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a report on Wednesday, October 2nd. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, PDS Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $14.25.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.